Dianthus Therapeutics (STU:87E) Cash Payments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:87E Dianthus Therapeutics Inc STU:87E
22 GF Score
Price €97.50
GF Value €3.38
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Dianthus Therapeutics Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

STU:87E
22GF Score
Dianthus Therapeutics Inc STU:87E
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Dianthus Therapeutics (STU:87E) Overvalued in 2026?

Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued. The current stock price of €97.50 is trading 2784.6% above its estimated GF Value™ of €3.38. GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:87E:

  • Cash Payments:
  • GF Value™: €3.38 vs. price of €97.50 (2784.6% above fair value)
  • GF Score™: 22/100 with 7 warning signs

No single metric tells the full story. See the STU:87E stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dianthus Therapeutics Business Description

Other Exchanges DNTH:USA
Address 7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score

Get the complete analysis for STU:87E

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€97.50
Price
€3.38
GF Value